Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.

Cancer letters - 28 Apr 2024

Xu Pingping, Gao Yaqi, Jiang Shanshan, Cui Yun, Xie Yuanhong, Kang Ziran, Chen Ying-Xuan, Sun Danfeng, Fang Jing-Yuan

Abstract excerpt

Immune checkpoint blockade (ICB) therapy has improved treatment effects in multiple cancers. Gene mutations in the DNA damage repair pathway (DDR) may cause genomic instability and may relate to the efficacy of ICB. Checkpoint kinase 2 (CHEK2) and polymerase epsilon (POLE) are important genes in the DDR. In this study, we aimed to study the impact of CHEK2 deficiency mutations on the response to ICB. We found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Tumor Microenvironment

Source

Identifiers

PMID: 38097135
DOI: 10.1016/j.canlet.2023.216595

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.PMID 38097135Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors.Semantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.Semantic proximity Read ↗

Potential Value of PRKDC as a Therapeutic Target and Prognostic Biomarker in Pan-CancerSemantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer.Semantic proximity Read ↗

PKMYT1 inhibition induces DNA damage and synergizes with immune checkpoint blockade in <i>CCNE1</i> -amplified gastroesophageal adenocarcinomaSemantic proximity Read ↗

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read ↗

PRKDC : new biomarker and drug target for checkpoint blockade immunotherapySemantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.